Skip to main content
Lung Cancer
ADAURA Trial: Osimertinib in Resected EGFR-Mutated NSCLC
Read More
Neuroendocrine Tumors
Neuroendocrine Year in Review Introduction
Read More
Neuroendocrine Tumors
CLARINET FORTE Study Results of Lanreotide Autogel in Progressive Pancreatic or Midgut NETs
Read More
Breast Cancer
Breast Cancer Year in Review Introduction
Read More
Breast Cancer
Retrospective Analysis Provides Insight into Treatment-Emergent Neutropenia Among Patients with Metastatic Breast Cancer Treated with Ribociclib or Palbociclib
Read More
Breast Cancer, CDK4/6 Inhibitors
Concurrent Use of Medications with Potential Drug–Drug Interactions: Real-World Analysis of Patients Treated with CDK4/6 Inhibitors
Read More
Breast Cancer
Abemaciclib plus Fulvestrant Provides Statistically Significant Benefit as First- and Second-Line Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
Read More
Breast Cancer
Preliminary Results from a Phase 2 Trial of Fulvestrant/Palbociclib as First-Line Therapy in Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Endocrine-Sensitive Advanced Breast Cancer
Read More
Breast Cancer
Ribociclib Added to Endocrine Therapy in Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Demonstrated Favorable Quality-of-Life Results
Read More
Breast Cancer, CDK4/6 Inhibitors
Examining Different Sequence Effects of CDK4/6 Inhibitor Combinations on Actual Real-World Outcomes of Treatment in Patients with Hormone Receptor–Positive and HER2-Negative Metastatic Breast Cancer
Read More
Page 102 of 197
Results 1011 - 1020 of 1963